Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06717438 · ClinicalTrials.gov registry record · Phase 2
Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])
A Phase 2 study of Jordan's Syndrome and PPP2R5D Neurodevelopmental Disorder, sponsored by Shionogi.
- Active
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 3
- Study locations
NCT06717438 is a Phase 2 study of Jordan's Syndrome and PPP2R5D Neurodevelopmental Disorder that is active but no longer recruiting, run by Shionogi. The registered enrollment target is 30 participants. The trial reports 3 study locations across 3 states.
The verdict
NCT06717438, a Phase 2 study of Jordan's Syndrome and PPP2R5D Neurodevelopmental Disorder, is active but no longer recruiting, sponsored by Shionogi.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 3
- Study locations
Study Summary
The primary objective of this study is to assess the safety and tolerability of BPN14770 in participants aged 9 to 45 years with JS.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG BPN14770
Study Locations (3)
Illinois
- Rush University Medical Center - Chicago
Massachusetts
- Boston Children's Hospital - Boston
Washington
- Seattle Children's Hospital - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-05-13 |
| Est. Completion | 2030-01-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06717438
The ClinicalTrials.gov registry entry for NCT06717438 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Shionogi, which has 54 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Jordan's Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06717438 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Illinois, Massachusetts, Washington.
Frequently Asked Questions
What is clinical trial NCT06717438 about?
NCT06717438 is a clinical study titled "Study of Zatolmilast (BPN14770) in Participants With PPP2R5D Neurodevelopmental Disorder (Jordan's Syndrome [JS])". The primary objective of this study is to assess the safety and tolerability of BPN14770 in participants aged 9 to 45 years with JS.
What is the current status of trial NCT06717438?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-05-13. Estimated completion is 2030-01-31.
What conditions does trial NCT06717438 study?
This clinical trial studies the following conditions: Jordan's Syndrome, PPP2R5D Neurodevelopmental Disorder.
What interventions are being tested in trial NCT06717438?
The interventions under investigation include: Placebo (DRUG), BPN14770 (DRUG).
Who is sponsoring clinical trial NCT06717438?
This trial is sponsored by Shionogi, which has 54 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06717438 being conducted?
This trial has 3 study locations across Illinois, Massachusetts, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.